A fresh Digital Health Cooperative Research Centre project will study the impact of an AI-powered diagnostic support solution on clinicians’ decision-making and patient management at the idea of care.
Led by Macquarie University, Sydney Local Health District, and medtech startup annalise.ai, the project will specifically check out the usage of the Annalise Enterprise CXR solution in assisting clinicians deliver effective and safe interpretations of chest x-rays in emergency departments. It’ll assess its effect on diagnostic accuracy, patient management, and cognitive load compared to current practice.
The Annalise chest x-ray interpretation tool can detect around 124 findings and localise those suspected findings on chest x-ray images.
WHY IT MATTERS
Although it is well known that AI can help doctors in clinical decision-making, its translated advantages to care quality and patient safety “remain largely unmeasured,” said DHCRC.
Given the short window of time for radiologists to examine and render a formal report on chest x-rays, especially sometimes of popular, the usage of AI can provide doctors a “more timely clue on which to check” for until they are able to get a full report, explained Professor Farah Magrabi of the Australian Institute of Health Innovation at Macquarie University.
Michael Dinh, founder and director of Royal Prince Alfred Hospitals Green Light Institute for Emergency Care, claimed that “[t]he ability for clinical staff to possess immediate usage of more descriptive findings will ultimately result in better outcomes for the patients”.
“Chest x-ray remains a core medical imaging diagnostic tool, and in emergency medicine, the necessity for accurate, time-critical clinical decisions is paramount,” added Dr Mark Phillips, annalise.ai’s head of Clinical Research and Medical Affairs.
THE BIGGER TREND
Sydney LHD can be leading another DHCRC project that seeks to judge and improve clinical decision-making across regional and metropolitan hospital settings in Australia. The study team is using Alcidion’s Miya Precision platform to recognize priority areas where decision support tools will add value to Australian hospitals.
In other news, annalise.ai just lately made key appointments since it sought to expand in to the USA. It named Lakshmi Gudapakkam as CEO and Dr Rick Abramson as CMO. Their appointments came following the company received a US Food and Drug Administration’s 510(k) clearance for Annalise Enterprise CXR in March.